Special Protection for Test Data Under TRIPS: Significance of Article 39(3)

When a pharmaceutical company spends years – and often hundreds of millions of dollars – generating clinical trial data to get a new drug approved, what stops a competitor from simply relying on that same data to gain regulatory clearance for their own product? This is precisely the question that Article 39(3) of the TRIPS Agreement was designed to address. As the WTO’s own module on undisclosed information notes, TRIPS is the first international instrument that contains obligations specifically for the protection of undisclosed test and other data required to obtain marketing approval for pharmaceutical or agricultural chemical products. Understanding Article 39(3) is essential for anyone studying intellectual property law, particularly because it sits at the intersection of trade secrets, public health, and the rights of innovators.

Where Article 39(3) fits within the TRIPS framework 🔗

Article 39 of TRIPS falls under Part II, Section 7, which deals with the “Protection of Undisclosed Information.” The provision is explicitly linked to Article 10bis of the Paris Convention (1967), which governs protection against unfair competition. This connection is critical – it tells us that the entire philosophy behind Article 39 is rooted in preventing commercially dishonest conduct, not necessarily in creating a new category of intellectual property rights akin to patents or copyright.

Article 39 has three paragraphs. Paragraph 1 sets the general framework by directing Member States to protect undisclosed information in line with the Paris Convention’s unfair competition principles. Paragraph 2 covers trade secrets more broadly. Paragraph 3 is the specific provision that imposes an obligation on Members to take affirmative steps to protect “undisclosed test or other data” from both “unfair commercial use” and “disclosure,” subject to the satisfaction of several conditions.

The text of Article 39(3): what it actually says 🔗

The full text, as reproduced by the WTO Analytical Index, reads:

“Members, when requiring, as a condition of approving the marketing of pharmaceutical or of agricultural chemical products which utilize new chemical entities, the submission of undisclosed test or other data, the origination of which involves a considerable effort, shall protect such data against unfair commercial use. In addition, Members shall protect such data against disclosure, except where necessary to protect the public, or unless steps are taken to ensure that the data are protected against unfair commercial use.”

Every word of this provision carries legal weight, and scholars have debated each element for over two decades. Let us break down the key conditions and obligations it sets out.

Conditions for protection under Article 39(3) 🔗

As legal commentary on the provision clarifies, protection under Article 39(3) is triggered only when all of the following conditions are simultaneously satisfied.

1. Data submitted for marketing approval 🔗

The protection applies only when Member States require submission of data as a condition of approving marketing. If a country permits approval based on a prior registration in another country – without requiring fresh data submission – Article 39(3) does not apply. As the Indian Government’s Satwant Reddy Committee Report clarified, Article 39(3) applies to data submitted to the National Regulatory Authority of a country, and would not apply where submission has been waived on the basis of an earlier marketing approval granted to the same drug in another jurisdiction.

2. Pharmaceutical or agricultural chemical products 🔗

The scope of Article 39(3) is restricted to two specific product categories: pharmaceutical products and agricultural chemical products. The TRIPS Agreement does not define either term, but they are understood in their ordinary sense – products used in pharmacy and agrichemical inputs like pesticides and herbicides respectively. Importantly, the provision does not extend to cosmetics, food supplements, or medical devices, even though similar data may be required for their regulatory approval.

3. New chemical entities 🔗

This is one of the most contested requirements in the entire provision. The data must relate to products that “utilize new chemical entities” (NCEs). The TRIPS Agreement deliberately avoids defining the term “new,” leading to two competing interpretations: absolute newness (new anywhere in the world) versus relative newness (new within the domestic regulatory system of that Member State). Most scholarly analysis suggests that “new” must refer to a chemical entity’s status in the Member’s domestic regulatory system rather than its global novelty. Critically, Article 39(3) would not apply to new applications of known substances, new dosage forms, combinations, new routes of administration, crystalline forms, or isomers of existing pharmaceuticals – because these do not involve a genuinely new chemical entity.

4. Undisclosed data 🔗

The data must be “undisclosed” – meaning it was not in the public domain at the time of submission and must continue to remain so. This condition ensures that the provision protects only genuinely confidential information. Once data enters the public domain through any means, the protection under Article 39(3) no longer applies to it.

5. Considerable effort 🔗

The data’s origination must have involved “a considerable effort.” The Agreement provides no definition or numeric threshold for what constitutes considerable effort. The accepted interpretation is that the effort must be substantial in both economic and technical or scientific terms. Generating safety and efficacy data through years of preclinical testing and multi-phase clinical trials – a process that routinely costs hundreds of millions of dollars – would clearly meet this threshold.

The two-fold obligation: protection against unfair commercial use and against disclosure 🔗

Once all the conditions above are met, Article 39(3) imposes two distinct obligations on Member States.

Protection against unfair commercial use 🔗

Protection under Article 39(3) is available independently of other intellectual property rights, including patents. Members must protect test data against unfair commercial use irrespective of whether the product in question is covered by a patent. This matters because patents and test data protections are conceptually distinct – a company may have invested heavily in generating clinical data even for a product that is not patented.

The phrase “unfair commercial use” is the most contested expression in the provision. Two broad interpretive camps exist. The first, championed largely by the United States and the pharmaceutical industry, equates unfair commercial use with any reliance by a generic manufacturer (or even a regulatory authority) on the originator’s data to approve a competing product, effectively demanding data exclusivity – a fixed period during which no other applicant can rely on the originator’s data. Under this view, even after a patent expires, a generic manufacturer cannot obtain marketing approval without conducting its own costly clinical trials if data exclusivity is in force.

The second interpretation, associated with scholars like Professor Carlos Correa, holds that the obligation is merely one of non-disclosure to private third parties – regulators themselves can still rely on the data to evaluate subsequent applications without that constituting “unfair commercial use.” A third, intermediate position advanced by Professor Shamnad Basheer suggests that Article 39(3) envisages a compensatory liability model – where reliance on originator data is permitted, but only upon paying compensation to the data originator, rather than granting outright exclusivity.

Protection against disclosure 🔗

The provision also requires Members to protect the data against disclosure to third parties. However, this obligation comes with two clearly stated exceptions. First, disclosure is permissible where it is necessary to protect the public – for instance, in a public health emergency. Second, disclosure is allowed where steps are taken to ensure the data remains protected against unfair commercial use even after it is disclosed, such as binding confidentiality obligations imposed on those who access the data.

The data exclusivity debate: protection or monopoly? 🔗

The central controversy around Article 39(3) is whether it mandates data exclusivity or merely a confidentiality obligation. Data exclusivity, as practiced in jurisdictions like the United States, means a defined period – typically five years for NCEs under the Hatch-Waxman Act of 1984 – during which generic manufacturers cannot rely on the originator’s regulatory data even if the patent on the drug has expired or was never granted. In the European Union, the model is structured as “8+2+1”: eight years of data exclusivity, two years of market exclusivity, and a possible one-year extension for new indications. Japan provides eight years for new drugs.

Critics argue that data exclusivity effectively creates a second layer of market monopoly stacked on top of existing patent protections – a form of “evergreening” that delays generic entry and keeps drug prices high. Proponents counter that without such protection, the enormous investments required to generate clinical safety and efficacy data would not be undertaken, particularly for diseases that affect smaller patient populations.

India’s position on Article 39(3) 🔗

India’s approach to Article 39(3) is particularly instructive. As legal scholarship from the National Law School documents, India constituted a special inter-ministerial committee in February 2004 – headed by Mrs. Satwant Reddy – to examine the data exclusivity issue. The committee’s final report recommended a differentiated approach: a data exclusivity regime for agrochemicals, but only a non-disclosure or confidentiality regime for the pharmaceutical sector, meaning a drug regulator could still rely on originator data to grant approvals to generics without that being treated as unfair commercial use.

The Government of India’s official stance has been that Article 39(3) only requires protection against “unfair commercial use” and does not mandate market exclusivity or data exclusivity. India has not enacted a standalone data exclusivity law, and inter-ministerial divisions have persisted. This position has drawn sustained pressure from the United States and European Union in bilateral trade negotiations, though India has largely maintained its position in the interest of preserving its generic pharmaceutical industry and access to medicines for its population.

This stance also reflects India’s broader reading of the Doha Declaration on TRIPS and Public Health (2001), which affirmed that the TRIPS Agreement should be interpreted and implemented in a manner supportive of WTO Members’ right to protect public health and promote access to medicines for all.

Article 39(3) and its relationship with public health 🔗

The tension between data protection and public health is inherent to Article 39(3). Scholars analyzing the Brazilian context have argued that the text of Article 39(3) needs to be read flexibly and in light of the objective of promoting access to medicines. Abbreviated approval processes – such as bioequivalence studies used to approve generic medicines – are important tools for fostering generic industries in developing countries, and a strict data exclusivity reading of Article 39(3) could undermine these.

There is also no WTO dispute settlement jurisprudence directly resolving the “unfair commercial use” question. The matter arose in the WTO dispute Argentina – Certain Measures on the Protection of Patents and Test Data (DS196), but the parties reached a mutually satisfactory solution without a panel ruling on this specific issue, leaving the interpretive question unresolved at the multilateral level.

Key takeaways on Article 39(3) 🔗

Article 39(3) established the first international standard for test data protection in the pharmaceutical and agrochemical sectors. Its key features can be summarized as follows. Protection is conditional – all five requirements (data submitted for approval, pharmaceutical or agricultural chemical product, new chemical entity, undisclosed status, considerable effort) must be met. The provision mandates protection against both unfair commercial use and disclosure, with two exceptions for the latter. The meaning of “unfair commercial use” remains unresolved, with interpretations ranging from full data exclusivity to mere non-disclosure to a compensatory liability model. Protection exists independently of any patent over the product. And crucially, the provision is a minimum standard – Member States are free to go beyond it, but TRIPS does not compel the most restrictive interpretation.

For Indian law students, Article 39(3) is a window into how international trade law shapes domestic pharmaceutical regulation, and how developing countries negotiate the space between TRIPS obligations and public health imperatives.

What do you think? Given that Article 39(3) leaves the meaning of “unfair commercial use” open to interpretation, should India adopt a compensatory liability model rather than either full data exclusivity or pure non-disclosure – and would such a model genuinely balance the interests of innovators and patients? If data exclusivity delays generic entry even after patent expiry, how should countries like India weigh the long-term incentive for pharmaceutical R&D against the immediate need for affordable medicines?

References

1. https://www.wto.org/english/tratop_e/trips_e/ta_docs_e/modules7_e.pdf
2. https://scholarlycommons.law.northwestern.edu/cgi/viewcontent.cgi?article=1883&context=njilb
3. https://www.wto.org/english/res_e/publications_e/ai17_e/trips_art39_oth.pdf
4. https://www.aequivic.in/post/data-exclusivity-and-trips
5. https://chemicals.gov.in/sites/default/files/Reports/DPBooklet%5B1%5D.pdf
6. https://spicyip.com/2015/03/data-exclusivity-back-on-the-table-for-india.html
7. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=934269
8. https://ijlsss.com/protecting-patients-or-patents-the-case-for-rethinking-data-exclusivity-in-indias-drug-regulatory-framework/
9. https://repository.nls.ac.in/cgi/viewcontent.cgi?article=1073&context=ijlt
10. https://www.legalserviceindia.com/article/l197-Data-Exclusivity-Law.html
11. https://link.springer.com/chapter/10.1007/978-3-030-03263-0_22